

**Amendments to the Claims:**

1. (Currently Amended) A succinate salt of 2S, 3S enantiomer of 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine, ~~which is the fumarate salt or the succinate salt thereof.~~
2. (Cancelled)
3. (Cancelled)
4. (Currently Amended) A pharmaceutical composition comprising the salt according to claim 1 in admixture ~~a with a salt, as claimed in claim 1, as active ingredient and a pharmaceutically acceptable excipient.~~
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Non-elected and Currently Amended) A mMethod for treating a mammal in need of selective norepinephrine reuptake inhibition comprising administering to said mammal a therapeutically acceptable amount of the salt according to claim 1. ~~a therapeutically effective amount of a salt of SS-reboxetine, which is the fumarate salt or the succinate salt thereof.~~
9. (Non-elected and Currently Amended) The A method, as claimed in claim 8, wherein the mammal is a human being.
10. (Non-elected and Currently Amended) A process for the preparation of the salt of claim 1 ~~a salt of 2S,3S enantiomer of 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine, which is the fumarate salt or the succinate salt thereof,~~ which comprises:
  - a) reacting 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine with (S) (+) mandelic acid so obtaining 2S, 3S 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine mandelate;
  - b) reacting said 2S, 3S 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine mandelate with a suitable basic agent so obtaining the corresponding free base<sub>i</sub>; and<sub>i</sub>

c) reacting said 2S, 3S 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine with ~~fumaric acid~~ or-succinic acid, ~~respectively~~, followed by a controlled crystallization process.

11. (Non-elected and Currently Amended ) The A method according to claim 8 wherein said condition is selected from the group consisting of an addictive disorder and withdrawal syndrome, an adjustment disorder, age-associated learning and mental disorder, anorexia nervosa, apathy, an attention-deficit disorder due to general medical conditions, attention-deficit hyperactivity disorder (ADHD), bipolar disorder, bulimia nervosa, chronic fatigue syndrome, chronic or acute stress, chronic pain, neuropathic pain, neuralgias including postherpetic neuralgias, conduct disorder, cyclothymic disorder, depression (including refractory depression, adolescent depression and minor depression), dysthymic disorder, fibromyalgia and other somatoform disorders, generalized anxiety disorder (GAD), incontinence, an inhalation disorder, intoxication disorder, mania, migraine headaches, obesity, obsessive compulsive disorders and related spectrum disorders, oppositional defiant disorder, panic disorder, peripheral neuropathy, diabetic neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, psychotic disorders, seasonal affective disorder, sleep disorders, social phobia, specific developmental disorders, selective serotonin reuptake inhibition (SSRI) "poop out" syndrome, and TIC disorders.

12. (Non-elected and Currently Amended) The A method according to claim 11 wherein the ~~addictive disorder comprises an addition to at least one of alcohol, nicotine, and other psychoactive substances~~ somatoform disorder is fibromyalgia.

13. (Cancelled)

14. (New) The salt according to claim 1 wherein the salt is crystalline.

15. (New) The salt according to claim 14 which is characterized by a powder X-ray diffraction pattern (PXRD) which shows at least one peak selected from the group consisting of 6.45, 12.85, 16.85, 21.20, and 24.05 degrees  $2\theta$ .

16. (New) The salt according to claim 14 which is characterized by a powder X-ray diffraction pattern (PXRD) which shows main peaks at 6.45, 12.85, 16.85, 21.20, and 24.05 degrees  $2\theta$ .

17. (New) The salt according to Claim 16 wherein the salt has at least one further powder X-ray diffraction pattern (PXRD) peak selected from the group consisting of 9.00, 18.10, 30.10 and 30.30 degrees  $2\theta$ .

18. (New) The salt according to Claim 16 wherein the salt has at least one further powder X-ray diffraction pattern (PXRD) peak selected from the group consisting of 19.30, 22.05, 25.70 and 30.90 degrees  $2\theta$ .

19. (New) The salt according to Claim 14 wherein the differential scanning calorimetry (DSC) trace shows a sharp endotherm at 148°C.